Vizsgálati helyszín
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland 20892, Egyesült ÁllamokMég nincs intézményhez kötve
- 16futó vizsgálat
- 1lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 19 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 1. fázis11 vizsgálat
- 2. fázis7 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz12 vizsgálat
- Toboroz4 vizsgálat
- Felfüggesztve2 vizsgálat
- Lezárult1 vizsgálat
- Fő szponzor
- National Cancer Institute (NCI)18 vizsgálat
- National Cancer Institute LAO1 vizsgálat
Futó vizsgálatok
Toboroz
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
NCT05711615· 1. fázis· National Cancer Institute (NCI)· Forrás
Contact: A P. Chen (principal investigator)
Fut, nem toboroz
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
NCT05836571· 2. fázis· National Cancer Institute LAO· Forrás
Toboroz
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT05691491· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Contact: A P. Chen (principal investigator)
Fut, nem toboroz
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT05691504· 1. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial
NCT05333458· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: A P. Chen (principal investigator)
Fut, nem toboroz
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
NCT05142241· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
NCT04491942· 1. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
NCT04535401· 1. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT04704661· 1. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
NCT04616534· 1. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
NCT04595747· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT04550494· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
NCT04458922· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345· 1. fázis· National Cancer Institute (NCI)· Forrás
Contact: A P. Chen (principal investigator)
Fut, nem toboroz
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
NCT03141684· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
NCT02298959· 1. fázis· National Cancer Institute (NCI)· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek